First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice

Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent nucleos(t)ide analogues (NUCs) recommended as first-line monotherapies for chronic hepatitis B. In Phase III trials, ETV and TDF demonstrated superior efficacy, and comparable safety compared with other NUCs. In long-term clinical st...

Descripción completa

Detalles Bibliográficos
Autores principales: Pol, S, Lampertico, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489060/
https://www.ncbi.nlm.nih.gov/pubmed/22571899
http://dx.doi.org/10.1111/j.1365-2893.2012.01602.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489060/
https://www.ncbi.nlm.nih.gov/pubmed/22571899
http://dx.doi.org/10.1111/j.1365-2893.2012.01602.x

Ejemplares similares